Mizuho lowered the firm’s price target on Embecta (EMBC) to $12 from $13 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMBC:
- Embecta price target lowered to $13 from $15 at Mizuho
- Embecta price target lowered to $25 from $26 at BTIG
- Embecta Corporation’s Strategic Transition and Financial Outlook: A Buy Rating Based on Growth Initiatives and Attractive Valuation
- Embecta Unveils Strategy at Analyst and Investor Day
- Cautious Outlook on Embecta Corporation Amidst Unclear Growth Catalysts and Margin Concerns